Abstract: A method of treating inflammation in patients in need of such treatment by administering an effective amount of I-A-B-C-D-E-F-G-H-II (General Formula), wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr, or absent, C is Ser, Thr or absent, D is Ser, Thr, Asn, Glu, Arg, Ile, Leu or absent, E is Ser, Thr, Asp or absent, F is Ser, Thr, Asp or absent, G is Tyr or absent, H is Thr, Arg, Gly, Met, Met(O), Cys, Thr, Gly or absent and I is Cys or absent II is Cys, an amide group, an ester group or absent. At least one of the amino acids optionally is substituted by a monomeric or polymeric carbohydrate or derivative thereof, such substitution being accomplished through hydroxyl and/or amino acid and/or amido groups of the amino acids, and wherein the peptide composes at least 4 amino acid residues, and a pharmaceutically acceptable salt thereof.

Abstract: Method of treating or ameliorating symptoms of T-cell mediated disease wherein a composition comprising a therapeutically effective amount of a polyunsaturated fatty acid and a pharmaceutically acceptable carrier is administered to the patient. The polyunsaturated fatty acid contains 18-25 carbon atoms, 1-6 double bonds and has 1 or 2 substitutions selected from &bgr; oxa, &ggr; oxa, &bgr; thia and &ggr; thia, based on the fatty acid acyl carbon atom, or the polyunsaturated fatty acid contains 16-26 carbon atoms, 3-double bonds and is covalently coupled at the carboxylic acid group to an amino acid.

Abstract: A method of treating or preventing multiple sclerosis in a patients in need of such treatment by administering an effect amount of the peptide: I-A-B-C-D-E-F-G-H-II (General Formula) wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr or absent, C is Ser, Thr or absent, D is Ser, Thr, Asn, Glu, Arg, IIe, Leu or absent, E is Ser, Thr, Asp or absent, F is Thr, Ser, Asn, Glu, Lys, Trp or absent, G is tyr or absent; H is Thr, Arg, Gly, Met, Met(O), Gys, Thr, Gly or absent, I is Cys or absent, II is Cys, an amide group, substituted amide group, an ester group or absent.

Abstract: The invention provides polyunsaturated fatty acid compounds having antimalarial and/or neutrophil stimulatory activity, or anti-inflammatory activity. The polyunsaturated fatty acids contain a 16-26 carbon chain, 3-6 double bonds and are covalently coupled at the carboxylic acid group to an amino acid. It is preferred that the fatty acid contains 18-22 carbons and that the amino acid is glycine or aspartic acid. Preferred compounds are .gamma.-linolenic acid-glycine, .alpha.-linolenic acid-glycine, arachidonic acid-aspartic acid, eicosapentaenoic acid-aspartic acid and docosahexaenoic acid-aspartic acid.

Abstract: The present invention provides peptides which have the ability to abrogate TNF toxicity and/or LPS toxicity. The present invention further relates to compositions including these peptides as the active ingredient and methods of anti-inflammatory treatment involving the administration of this composition. The peptides of the present invention are based primarily on residue 1 to 26 of human TNF.

Abstract: A method of treating inflammatory bowel disease in patients in need of such treatment by administering an effective amount of: I-A-B-C-D-E-F-G-H-II (General Formula I), wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr, or absent, C is Ser, Thr or absent. D is Ser, Thr, Asn, Glu, Arg, IIe, Leu or absent, E is Ser, Thr, Asp or absent, F is Ser, Thr, Asp or absent, G is Tyr or absent, H is Thr, Arg, Gly, Met, Met(O), Cys, Thr, Gly or absent, and I is Cys or absent II is Cys, an amide group, substituted amid group, an ester group or absent. At least one of the amino acids optionally being substituted by a monomeric or polymeric carbohydrate or derivative thereof, such substitution being accomplished through hydroxyl and/or amino and/or amido groups of the amino acids, and wherein the peptide comprises at least 4 amino acid residues, and a pharmaceutically acceptable salt thereof.

Abstract: Small peptidic compounds containing a small and branched chained amino acid residue, pharmaceutical compositions containing at least one such compound active against glaucoma and intraocular hypertension and a method for treating glaucoma and intraocular hypertension.

Abstract: Peptide derivatives of 3-5 optionally substituted amino acids, a process for preparing the peptides, a pharmaceutical composition containing at least one peptide derivative active against glaucoma and intraocular hypertension and a method for treating glaucoma and intraocular hypertension.

Abstract: A peptide having the formulaA--Bwherein A represents an N-terminal protected amino acid residue or an optionally N-terminal protected peptide residue and B represents an optionally C-terminal protected amino acid residue, is prepared by reacting a substrate component selected from the group consisting of optionally N-terminal protected peptides of the formulaA--Xwherein A is as defined above and X represents an amino acidwith an amine component selected from the group consisting of(a) amino acids of the formulaH--B--OH,(b) optionally N-substituted amino acid amides of the formulaH--B--NHR.sup.3wherein B is an amino acid residue and R.sup.3 represents hydrogen, hydroxy, amino or alkyl, aryl or aralkyl, and(c) amino acid esters of the formula H--B--OR.sup.4 or H--B--SR.sup.4 wherein B is an amino acid residue and R.sup.4 represents alkyl, aryl and aralkyl,in the presence of a carboxypeptidase enzyme in an aqueous solution or dispersion having a pH from 5 to 10.5, preferably at a temperature of from 30 to 50.

Abstract: The B-30 amino acid in insulins is replaced enzymatically byreacting as substrate component the selected insulin Ins-X, wherein X represents the B-30 amino acidwith an amine component selected from the group consisting of(a) amino acids of the formulaH--B--OHwherein B is an amino acid residue,(b) optionally N-substituted amino acid amides of the formulaH--B--NR.sup.1 R.sup.2wherein B is an amino acid residue and R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, amino, hydroxy, alkyl, cycloalkyl, aryl, heteroaryl and aralkyl or R.sup.1 and R.sup.2 together with the nitrogen atom form a heterocyclic group which may contain a further hetero atom, and(c) amino acid esters of the formulaH--B--OR.sup.3, H--B--SR.sup.3 or H--B--SeR.sup.3wherein B is am amino acid residue and R.sup.

Abstract: A peptide having the formulaA--Bwherein A represents an N-terminal protected amino acid residue or an optionally N-terminal protected peptide residue and B represents an optionally C-terminal protected amino acid residue, is prepared byreacting a substrate component selected from the group consisting of(a) amino acid esters, peptide esters and depsipeptides of the formulaA--OR.sup.1 or A--SR.sup.1wherein A is as defined above and R.sup.1 represents alkyl, aryl, aralkyl or an .alpha.-des-amino fragment of an amino acid residue,(b) optionally N-substituted amino acid amides and peptide amides of the formulaA--NHR.sup.2wherein A is as defined above and R.sup.2 represents hydrogen, alkyl, aryl or aralkyl, and(c) optionally N-terminal protected peptides of the formulaA--Xwherein A is as defined above and X represents an amino acidwith an amine component selected from the group consisting of(a) amino acids of the formulaH--B--OH,(b) optionally N-substituted amino acid amides of the formulaH--B--NHR.sup.